[1]陈玥舟 张文彭 朱建平 王娅楠.藏药Padma 28在国外的临床研究[J].国际中医中药杂志,2012,34(07):646-650.[doi:10.3760/cma.j.issn.1673-4246.2012.07.024]
 [J].,2012,34(07):646-650.[doi:10.3760/cma.j.issn.1673-4246.2012.07.024]
点击复制

藏药Padma 28在国外的临床研究

参考文献/References:

[1] Padma AG. Translation of the Product Information for Patients of the “Arzneimittel-Kompendium der Schweiz?”,[online]available. [2009-9-29]. http://www.padma.ch/en/products/ padma-28/faq/production.html.
[2] 张文彭,Е.В.Владимирский,Ф.Е.Аркадий,等. 藏医药学在俄罗斯的传播与巴德玛耶夫家族的贡献. 国际中医中药杂志,2012,34(5):385-389.
[3] Melzer J,Brignoli R,Diehm C,et al. Treating intermittent claudication with Tibetan medicine Padma 28: Does it work? Artherosclerosis,2006,189(1):39-46.
[4] Hürlimann F. A lamaistic formula for the treatment of peripheral arterial occlusive disease. Schweiz Rundschau Med (PRAXIS),1978,67(38):1407-1409.
[5] Brzosko WJ,Jankowski A. PADMA 28 in patients with chronic hepatitis B: Clinical and immunological effects Schweiz Zschr für Ganzheits Medizin,1992,(7/8 Suppl 1):13-14.
[6] Korwin-Piotrowska T,Nocon D,Stankowska-Chomicz A,et al. Experience of PADMA 28 in Multiple Sclerosis. Phytotherapy Research,1992,6(3):133-136.
[7] Jankowski A,Jankowska R,Brzosko WJ. Treatment of children prone to infection with PADMA 28. Schweiz Zschr für GanzheitsMedizin,1992,4(7/8 Suppl. 1):22-23.
[8] Zebrowski MR E. The role of regulatory systems in inflammatory heart disease. Erfahrungsheilkunde,2004,53:81-88.
[9] Füllemann F. Padma 28 in the treatment of chronic dental pulpitis: an observational case study in 49 patients. Forsch Komplementärmed,2006,13(Suppl. 1):28-30.
[10] Melzer J,Brignoli R,Saller R. Efficacy and safety of Padma 28 in peripheral arterial occlusive disease Forsch Komplementarmed,2006,13(Suppl. 1):23-27.
[11] Criqui MH. Peripheral arterial disease-epidemiological aspects. Vasc Med,2001,6(Suppl. 3):3-7.
[12] Schräder R,Nachbur B,Mahler F. Effects of the Tibetan herbal preparation Padma 28 in intermittent claudication. Schweiz Med Wochenschr,1985,115(22):752-756.
[13] Samochowiec Lb,Wojcicki J,Kosmider K,et al. Clinical test of the effectiveness of PADMA 28 in the treatment of patients with chronic arterial occlusion (Intermittent claudication Fontaine Stage II). Part I Herba Polonica,1987,XXXIII/1:29-41
[14] Sommoggy S,Schleicher P. Therapy of PAOD with Padma 28 Study I—Clinical and immunological effects of Padma 28 in patients with PAOD stage II according to Fontaine, Unpublished final report supplied by Department of Vascular Surgery, Technical University Munich & Zytognost GmbH, Munich[1990-6-26].
[15] Smulski HS,Wojcicki J. Placebo-controlled double-blind study to investigate the efficacy of the Tibetan plant preparation Padma 28 in the treatment of intermittent claudication. Forsch Komplementärmedizin,1994,1:18-26.
[16] Drabaek H,Mehlsen J,Himmelstrup H,et al. A botanical compound, Padma 28, increases walking distance in stable intermittent claudication. Angiology,1993,44(11):863-867.
[17] Sallon S,Beer G,Rosenfeld J,et al. The efficacy of Padma 28, a herbal preparation, in the treatment of intermittent claudication: a controlled double blind pilot study with objective assessment of chronic occlusive arterial disease patients. Journal of Vascular Investigation,1998,4:129-136.
[18] Wojcicki J,Samochowiec L. Controlled double-blind study of Padma 28 in Angina Pectoris. Herba Polonica,1986,32:107-114.
[19] De Bac C,Taliani G,Furlan C,et al. Significant reduction of viral activity in carriers of HBs after receiving an herbal drug with immunomodulant effect. J of Hepatology,1985,1(Suppl 1):46.
[20] Nefyodov LI,Doroshenko YM,Karavay NL,et al. Effect of PADMA 28 on impaired amino acid metabolism induced by liver inflammatory pathology. Herba Polonica,2000,46(4):340-345.
[21] Jankowski A,Drabik E,Szysko Z,et al. Treatment with PADMA 28 of children with recurrent infections of the respiratory tract. Therapiewoche Schweiz,1986,2(1):25-32.
[22] Prusek W,Jankowski A,Radomska G,et al. Immunostimulation in recurrent respiratory tract infections therapy in children. Archivum Immunologiaeet Therapiae Experimentalis,1987,35(3):289-302.
[23] Bowling AC,Stewart TM. Current Complementary and Alternative Therapies for Multiple Sclerosis. Curr Treat Options Neurol,2003,5(1):55-68.
[24] Gingsburg I,Sadovnik M,Sallon S,et al. Padma 28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammopharmacology,1999,7(1):47-62.
[25] Suter M,Richter Ch. Anti- and pro-oxidative properties of PADMA 28, a Tibetan herbal formulation . Redox Report,2000,5(1):17-22.
[26] Matzner Y,Sallon S. The Effect of Padma 28, a Traditional Tibetan Herbal Preparation, on Human Neutrophil Function. J Clin Lab Immun,1995,46(1):13-23.
[27] Barak V,Kalickman I,Halperin T,et al. PADMA-28, a Tibetan herbal preparation is an inhibitor of inflammatory cytokine production. Eur Cytokine Netw,2004,15(3):203-209.
[28] Neurauter G,Wirleitner B,Schroecksnadel K,et al. PADMA 28 modulates interferon-gamma-induced tryptophan degradation and neopterin production in human PBMC in vitro. Int Immunopharmacol,2004,4(6):833-839.
[29] Moeslinger T,Friedl R,Volf I,et al. Inhibition of inducible nitric oxide synthesis by the herbal preparation Padma 28 in macrophage cell line. Can J Physiol Pharmacol,2000,78(11):861-866.
[30] Exner M,Raith M,Holzer G,et al. Anti-inflammatory mechanisms of the Tibetan herbal preparation Padma 28 in the vessel wall. Forsch Komplementmed,2006,13(Suppl 1):13-17.
[31] Navab R,Aingorn H,Fallavollita L,et al. PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I. Inflammopharmacology,2004,12(4):373-389.

备注/Memo

基金项目:中国中医科学院基本科研业务费自主选题创新团队重点项目(项目编号:ZZ060801)
通信作者:张文彭,Email:168zhwp@sina.com;朱建平,Email:zhujpzhujp@yahoo.com.cn

更新日期/Last Update: